Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Cocaine abuse and addiction remain great challenges on the public health agendas in the U.S. and the world. Increasingly sophisticated perspectives on addiction to cocaine and other drugs of abuse have evolved with concerted research efforts over the last 30 years. Relapse remains a particularly powerful clinical problem as, even upon termination of drug use and initiation of abstinence, the recidivism rates can be very high. The cycling course of cocaine intake, abstinence and relapse is tied to a multitude of behavioral and cognitive processes including impulsivity (a predisposition toward rapid unplanned reactions to stimuli without regard to the negative consequences), and cocaine cue reactivity (responsivity to cocaine-associated stimuli) cited as two key phenotypes that contribute to relapse vulnerability even years into recovery. Preclinical studies suggest that serotonin (5-hydroxytryptamine; 5-HT) neurotransmission in key neural circuits may contribute to these interlocked phenotypes well as the altered neurobiological states evoked by cocaine that precipitate relapse events. As such, 5-HT is an important target in the quest to understand the neurobiology of relapse-predictive phenotypes, to successfully treat this complex disorder and improve diagnostic and prognostic capabilities. This review emphasizes the role of 5-HT and its receptor proteins in key addiction phenotypes and the implications of current findings to the future of therapeutics in addiction. This article is part of a Special Issue entitled 'NIDA 40th Anniversary Issue'.

Original languageEnglish (US)
Pages (from-to)460-478
Number of pages19
JournalNeuropharmacology
Volume76
Issue numberPART B
DOIs
StatePublished - 2014

Fingerprint

Cocaine-Related Disorders
Impulsive Behavior
Cues
Serotonin
Cocaine
Recurrence
Phenotype
Neurobiology
Serotonin Receptors
Street Drugs
Anniversaries and Special Events
Synaptic Transmission
Public Health
Nexus
Research
Pharmaceutical Preparations
Proteins

Keywords

  • Addiction
  • Cocaine
  • Cue reactivity
  • Dependence
  • Impulsivity
  • Serotonin

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction. / Cunningham, Kathryn; Anastasio, Noelle.

In: Neuropharmacology, Vol. 76, No. PART B, 2014, p. 460-478.

Research output: Contribution to journalArticle

@article{0056b019993d49a1892f63aa6f8d1b7f,
title = "Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction",
abstract = "Cocaine abuse and addiction remain great challenges on the public health agendas in the U.S. and the world. Increasingly sophisticated perspectives on addiction to cocaine and other drugs of abuse have evolved with concerted research efforts over the last 30 years. Relapse remains a particularly powerful clinical problem as, even upon termination of drug use and initiation of abstinence, the recidivism rates can be very high. The cycling course of cocaine intake, abstinence and relapse is tied to a multitude of behavioral and cognitive processes including impulsivity (a predisposition toward rapid unplanned reactions to stimuli without regard to the negative consequences), and cocaine cue reactivity (responsivity to cocaine-associated stimuli) cited as two key phenotypes that contribute to relapse vulnerability even years into recovery. Preclinical studies suggest that serotonin (5-hydroxytryptamine; 5-HT) neurotransmission in key neural circuits may contribute to these interlocked phenotypes well as the altered neurobiological states evoked by cocaine that precipitate relapse events. As such, 5-HT is an important target in the quest to understand the neurobiology of relapse-predictive phenotypes, to successfully treat this complex disorder and improve diagnostic and prognostic capabilities. This review emphasizes the role of 5-HT and its receptor proteins in key addiction phenotypes and the implications of current findings to the future of therapeutics in addiction. This article is part of a Special Issue entitled 'NIDA 40th Anniversary Issue'.",
keywords = "Addiction, Cocaine, Cue reactivity, Dependence, Impulsivity, Serotonin",
author = "Kathryn Cunningham and Noelle Anastasio",
year = "2014",
doi = "10.1016/j.neuropharm.2013.06.030",
language = "English (US)",
volume = "76",
pages = "460--478",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "PART B",

}

TY - JOUR

T1 - Serotonin at the nexus of impulsivity and cue reactivity in cocaine addiction

AU - Cunningham, Kathryn

AU - Anastasio, Noelle

PY - 2014

Y1 - 2014

N2 - Cocaine abuse and addiction remain great challenges on the public health agendas in the U.S. and the world. Increasingly sophisticated perspectives on addiction to cocaine and other drugs of abuse have evolved with concerted research efforts over the last 30 years. Relapse remains a particularly powerful clinical problem as, even upon termination of drug use and initiation of abstinence, the recidivism rates can be very high. The cycling course of cocaine intake, abstinence and relapse is tied to a multitude of behavioral and cognitive processes including impulsivity (a predisposition toward rapid unplanned reactions to stimuli without regard to the negative consequences), and cocaine cue reactivity (responsivity to cocaine-associated stimuli) cited as two key phenotypes that contribute to relapse vulnerability even years into recovery. Preclinical studies suggest that serotonin (5-hydroxytryptamine; 5-HT) neurotransmission in key neural circuits may contribute to these interlocked phenotypes well as the altered neurobiological states evoked by cocaine that precipitate relapse events. As such, 5-HT is an important target in the quest to understand the neurobiology of relapse-predictive phenotypes, to successfully treat this complex disorder and improve diagnostic and prognostic capabilities. This review emphasizes the role of 5-HT and its receptor proteins in key addiction phenotypes and the implications of current findings to the future of therapeutics in addiction. This article is part of a Special Issue entitled 'NIDA 40th Anniversary Issue'.

AB - Cocaine abuse and addiction remain great challenges on the public health agendas in the U.S. and the world. Increasingly sophisticated perspectives on addiction to cocaine and other drugs of abuse have evolved with concerted research efforts over the last 30 years. Relapse remains a particularly powerful clinical problem as, even upon termination of drug use and initiation of abstinence, the recidivism rates can be very high. The cycling course of cocaine intake, abstinence and relapse is tied to a multitude of behavioral and cognitive processes including impulsivity (a predisposition toward rapid unplanned reactions to stimuli without regard to the negative consequences), and cocaine cue reactivity (responsivity to cocaine-associated stimuli) cited as two key phenotypes that contribute to relapse vulnerability even years into recovery. Preclinical studies suggest that serotonin (5-hydroxytryptamine; 5-HT) neurotransmission in key neural circuits may contribute to these interlocked phenotypes well as the altered neurobiological states evoked by cocaine that precipitate relapse events. As such, 5-HT is an important target in the quest to understand the neurobiology of relapse-predictive phenotypes, to successfully treat this complex disorder and improve diagnostic and prognostic capabilities. This review emphasizes the role of 5-HT and its receptor proteins in key addiction phenotypes and the implications of current findings to the future of therapeutics in addiction. This article is part of a Special Issue entitled 'NIDA 40th Anniversary Issue'.

KW - Addiction

KW - Cocaine

KW - Cue reactivity

KW - Dependence

KW - Impulsivity

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=84887042833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887042833&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2013.06.030

DO - 10.1016/j.neuropharm.2013.06.030

M3 - Article

C2 - 23850573

AN - SCOPUS:84887042833

VL - 76

SP - 460

EP - 478

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - PART B

ER -